ReviewFrontiers in immunology2026
PANoptosis nexus in ischemia-reperfusion injury: from integrated cell death mechanisms to novel therapeutic opportunities.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion injury (IRI) can activate multiple cell death pathways, leading to dysfunction of multiple organs. PANoptosis is a new inflammatory cell death form recently discovered and it is also an integrated cell death mode, which includes the features of pyroptosis, apoptosis, necroptosis. Rather than a simple addition of these routes, PANoptosis is a special type of biology process with its own regulatory mechanism and plays an important regulatory role in the occurrence of IRI. The review focuses on the concept of PANoptosis, elaborating on its molecular mechanisms and detection methods, with a particular emphasis on exploring the regulatory networks of PANoptosis in various IRI. In addition, various potential treatment strategies targeting PANoptosis analyzed in depth, including small molecule inhibitors, natural products, gene intervention, and stem cell therapy. The overall goal is to clarify the importance of PANoptosis in the pathological mechanism of IRI and to explore the possibility of using it as a focus for clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.